Summary
A.P. PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €1.4m and a net result of €147,327. Equity is growing by about 15% per year across the filed financial years. Its solvency ranks better than 54% of 6,680 sector peers (NACE 64, financial year 2025). The company has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
11-10
Gazette deed
Resignation: PAUWELS Annelies (director)Reappointment: PAUWELS Annelies (director) · Purpose change · Capital conversion14 facts ▸
- General meeting, 28-09-2022
- Other provision, “verschijnende partijen, voormeld verslag” (deed in Dutch)
- Other provision, “kennisname verslagen, volledig in kennis gesteld” (deed in Dutch)
- Purpose change
- Other provision, “aanpassing statuten aan WVV en behoud rechtsvorm BV, besloten vennootschap” (deed in Dutch)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Reserve release, “vormen en meerderheden van statutenwijziging, opheffing statutair onbeschikbare eigen vermogensrekening en beschikbaarstelling voor uitkering” (deed in Dutch)
- Amendment of the articles
- Share issue, 100, “vergoeding voor inbrengen” (deed in Dutch)
- Other provision, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Director resignation, PAUWELS Annelies (director)
- Director reappointment, PAUWELS Annelies (director (not named in the articles))
- +2 further facts in this act
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.